版本:
中国

BRIEF-Achaogen starts C-Scape clinical development program with phase 1 study of orally-administered antibacterial candidate

June 1 Achaogen Inc

* Initiates c-scape clinical development program with phase 1 study of orally-administered antibacterial candidate

* Says preclinical studies have confirmed c-scape's potent in vitro microbiologic activity against esbl-producing enterobacteriaceae Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐